PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities. 

Looking for a new role? Please visit our careers page to find out more about our open jobs and benefits at https://phasebio.com/careers/

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21
revenue			668K -	2.36M 253.44%	320K 86.45%	10.83K 96.62%
cost of revenue					319.68K -
gross profit			668K -	2.36M 253.44%	320 99.99%	10.83K 3,284.69%
selling and marketing expenses
general and administrative expenses	2.13M -	2.33M 9.55%	4.86M 108.63%	11.19M 130.31%	13.09M 17.00%	16.09K 99.88%
selling general and administrative expenses	2.13M -	2.33M 9.55%	4.86M 108.63%	11.19M 130.31%	13.09M 17.00%	16.09K 99.88%
research and development expenses	7.38M -	6.21M 15.81%	15.46M 148.87%	30.91M 100.01%	72.09M 133.21%	102.11K 99.86%
other expenses
cost and expenses	9.50M -	8.54M 10.14%	20.31M 137.90%	42.10M 107.25%	85.18M 102.33%	118.19K 99.86%
operating expenses	9.50M -	8.54M 10.14%	20.31M 137.90%	42.10M 107.25%	85.18M 102.33%	118.19K 99.86%
interest expense		2.72M -	3.92M 44.11%	1.08M 72.58%	1.45M 34.29%	-947 100.07%
ebitda	-9.13M -	-7.43M 18.62%	-19.82M 166.79%	-38.00M 91.74%	-96.61M 154.26%	1.66M 101.72%
operating income	-9.50M -	-8.54M 10.14%	-19.64M 130.08%	-39.74M 102.28%	-84.86M 113.55%	-130.42K 99.85%
depreciation and amortization	92K -	96K 4.35%	105K 9.38%	174K 65.71%	508K 191.95%	1.79M 252.95%
total other income expenses net	281K -	-1.71M 708.19%	-4.20M 145.87%	489K 111.64%	-13.71M 2,903.48%	947 100.01%
income before tax	-9.22M -	-10.25M 11.14%	-23.85M 132.71%	-39.25M 64.59%	-98.56M 151.14%	-129.47K 99.87%
income tax expense	281K -	1.01M 260.85%	-278K 127.42%	1.56M 662.95%	-12.26M 883.64%	1.60K 100.01%
net income	-9.22M -	-10.25M 11.14%	-23.85M 132.71%	-39.25M 64.59%	-98.56M 151.14%	-131.07K 99.87%
weighted average shs out	12.39M -	11.25M 9.21%	5.31M 52.85%	27.49M 418.25%	29.06M 5.68%	29.40M 1.18%
weighted average shs out dil	12.39M -	11.25M 9.21%	5.31M 52.85%	27.49M 418.25%	29.06M 5.68%	29.40M 1.18%
eps	-0.74 -	-0.91 22.97%	-4.49 393.41%	-1.43 68.15%	-3.39 137.06%	-0.00 99.87%
epsdiluted	-0.74 -	-0.91 22.97%	-4.49 393.41%	-1.43 68.15%	-3.39 137.06%	-0.00 99.87%

COM:PHASEBIO

PhaseBio Pharmaceuticals, Inc.

Last Close

0.07

17/09 20:00

Volume Today

8.56M

Avg: -

Preview